CHD1L Inhibitor Program
Cancers with CHD1L overexpression (e.g., liver, breast, lung, colon)
Key Facts
About Onconaut Therapeutics
Onconaut Therapeutics is a private, preclinical biotech startup pioneering a novel approach to oncology by targeting the CHD1L oncogene, a driver of aggressive tumor behavior and therapy resistance. The company is advancing a series of small molecule inhibitors through IND-enabling studies, with an initial focus on cancers such as liver, breast, lung, and colon where CHD1L overexpression correlates with poor outcomes. Leveraging foundational academic research, Onconaut's strategy is to develop best-in-class therapies that enhance the efficacy of current treatments and reduce recurrence risk. As a pre-revenue entity, its near-term goal is to achieve clinical validation of its lead candidates.
View full company profile